AbCellera Biologics Inc vs AdaptHealth Corp — how do they compare? AbCellera Biologics Inc trades at $10.34 (market cap $2.99B), while AdaptHealth Corp trades at $5.75 (market cap $753.09M). The key difference: AbCellera Biologics Inc is far larger — about 4× AdaptHealth Corp's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | AHCO | |
|---|---|---|
Market Cap | $2.99B | $753.09M |
Sector | Health | Health |
52-Week High | $9.76 | $13.38 |
52-Week Low | $2.78 | $5.22 |
Enterprise Value | $2.58B | $2.77B |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
AdaptHealth Corp. (AHCO) trades at $5.74, up 9.96% in the last session, yet remains under pressure with a bearish technical signal and recent earnings misses. The company reported a Q2 2026 net loss of $228 million with a -6.82% margin, while selling its diabetes unit to focus on sleep and respiratory care. Valuation ratios show a low P/S of 0.23 and P/B of 0.55, but negative profitability metrics highlight operational challenges.
The outlook is mixed: analyst consensus is bullish with a $11 price target, but risks include ongoing losses, fraud investigations, and cost overruns in fixed-price contracts. Upside depends on successful business restructuring and margin improvement, while downside risks from legal and execution issues persist.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →